Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells

被引:17
作者
Spence, MJ
Streiff, R
Day, D
Ma, YS
机构
[1] Dept Vet Affairs Med Ctr, Med Res Serv, Boise, ID 83702 USA
[2] Mt States Med Res Inst, Boise, ID 83712 USA
[3] Mt States Tumor Inst, Boise, ID 83712 USA
[4] Mol Innovat Inc, Southfield, MI 48034 USA
关键词
oncostatin M; lung carcinoma; tissue-type plasminogen activator; plasminogen activator inhibitor-1; MEK1/2; pathway;
D O I
10.1006/cyto.2001.1018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oncostatin M (OSM) is a glycoprotein cytokine that is produced by activated T-lymphocytes, monocytes, and macrophages. In a DNA synthesis assay, OSM reduced tritiated thymidine incorporation by 53% in Calu-1 lung carcinoma cells. Radiolabeled cDNAs from untreated Calu-1 cells and 30-h OSM-treated cells were used to probe duplicate nylon membrane cDNA expression arrays. This study revealed OSM-mediated expression of mRNAs encoding tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). Northern blot analysis showed that the steady-state level of tPA mRNA is nearly undetectable in Calu-1 cells. Exposure of these cells to OSM for 30 h increased tPA mRNA expression by 20-fold and PAI-1 mRNA expression by 5-fold. Exposure of these cells to other gp130 receptor family cytokines, including leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and IL-11, do not significantly affect DNA synthesis or induction of tPA/PAI-1. Western blot studies demonstrated that OSM mediates a marked increase in secretion of the tPA protein. Secreted tPA was present in the conditioned medium almost exclusively as tPA/PAI-1 complexes. Inhibitor studies demonstrated that OSM-mediated induction of tPA and PAI-1 mRNAs is largely dependent upon activation of the MEK1/2 pathway. The JAK3/STAT3 pathway potentially serves a secondary role in these regulatory events. (C) 2002 Elsevier Scienct Ltd. All rights reserved.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 38 条
  • [1] TISSUE-TYPE PLASMINOGEN ACTIVATOR-INDUCED INVASION AND METASTASIS OF MURINE MELANOMAS
    ALIZADEH, H
    MA, D
    BERMAN, M
    BELLINGHAM, D
    COMERFORD, SA
    GETHING, MJH
    SAMBROOK, JF
    NIEDERKORN, JY
    [J]. CURRENT EYE RESEARCH, 1995, 14 (06) : 449 - 458
  • [2] Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
  • [3] 2-Z
  • [4] Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
    Barille, S
    Akhoundi, C
    Collette, M
    Mellerin, MP
    Rapp, MJ
    Harousseau, JL
    Bataille, R
    Amiot, M
    [J]. BLOOD, 1997, 90 (04) : 1649 - 1655
  • [5] NEUROPOIETIC CYTOKINES IN THE HEMATOPOIETIC FOLD
    BAZAN, JF
    [J]. NEURON, 1991, 7 (02) : 197 - 208
  • [6] PROGNOSTIC-SIGNIFICANCE OF PROTEOLYTIC-ENZYMES IN HUMAN BRAIN-TUMORS
    BINDAL, AK
    HAMMOUD, M
    SHI, WM
    WU, SZ
    SAWAYA, R
    RAO, JS
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1994, 22 (02) : 101 - 110
  • [7] BROWN TJ, 1987, J IMMUNOL, V139, P2977
  • [8] Cawston TE, 1998, ARTHRITIS RHEUM-US, V41, P1760, DOI 10.1002/1529-0131(199810)41:10<1760::AID-ART8>3.0.CO
  • [9] 2-M
  • [10] Changing views of the role of matrix metalloproteinases in metastasis
    Chambers, AF
    Matrisian, LM
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (17) : 1260 - 1270